- Home
- SOLV vs UTHR Comparison
SOLV vs UTHR Comparison
Compare SOLV & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- UTHR
- Stock Information
- Founded
- SOLV 2023
- UTHR 1996
- Country
- SOLV United States
- UTHR United States
- Employees
- SOLV N/A
- UTHR N/A
- Industry
- SOLV
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- UTHR Health Care
- Exchange
- SOLV NYSE
- UTHR Nasdaq
- Market Cap
- SOLV 12.6B
- UTHR 14.4B
- IPO Year
- SOLV N/A
- UTHR 1999
- Fundamental
- Price
- SOLV $74.74
- UTHR $306.97
- Analyst Decision
- SOLV Hold
- UTHR Buy
- Analyst Count
- SOLV 10
- UTHR 12
- Target Price
- SOLV $79.86
- UTHR $388.25
- AVG Volume (30 Days)
- SOLV 1.2M
- UTHR 492.5K
- Earning Date
- SOLV 04-07-2025
- UTHR 04-30-2025
- Dividend Yield
- SOLV N/A
- UTHR N/A
- EPS Growth
- SOLV N/A
- UTHR 24.38
- EPS
- SOLV 2.76
- UTHR 24.64
- Revenue
- SOLV $8,254,000,000.00
- UTHR $2,877,400,000.00
- Revenue This Year
- SOLV $2.35
- UTHR $11.70
- Revenue Next Year
- SOLV $1.67
- UTHR $6.50
- P/E Ratio
- SOLV $27.08
- UTHR $12.40
- Revenue Growth
- SOLV 0.69
- UTHR 23.63
- 52 Week Low
- SOLV $47.16
- UTHR $221.53
- 52 Week High
- SOLV $85.92
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- UTHR 39.02
- Support Level
- SOLV N/A
- UTHR $308.43
- Resistance Level
- SOLV N/A
- UTHR $318.40
- Average True Range (ATR)
- SOLV 0.00
- UTHR 9.26
- MACD
- SOLV 0.00
- UTHR 1.20
- Stochastic Oscillator
- SOLV 0.00
- UTHR 29.88
About SOLV SOLVENTUM CORP
Solventum Corp is an independent healthcare company with a primary focus on addressing healthcare challenges. Its diverse product portfolio spans the healthcare industry, including medical solutions, oral care, health information systems, and separation and purification sciences.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.